IceCure Medical Ltd. has filed proxy materials for a special general meeting of shareholders scheduled for November 19, 2026. The company is seeking authorization to effect one or more reverse share splits at ratios determined by the board within a range of 5-for-1 to 40-for-1 over the next 24 months. This proposal aims to maintain compliance with Nasdaq’s $1.00 minimum bid price requirement and preserve the company's listing status. The board unanimously recommends voting in favor of the resolution, which requires a simple majority for approval. IceCure Medical Ltd. operates in the medical device industry, developing minimally invasive cryoablation systems for cancer treatment.
